中国当代医药
中國噹代醫藥
중국당대의약
China Modern Medicine
2015年
29期
135-137
,共3页
溃疡性结肠炎%美沙拉嗪%双歧三联活菌%临床效果
潰瘍性結腸炎%美沙拉嗪%雙歧三聯活菌%臨床效果
궤양성결장염%미사랍진%쌍기삼련활균%림상효과
Ulcerativecolitis%Mesalazine%Dichotomous sanlian living bacterium%Clinical effect
目的：分析美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎(UC)的临床效果。方法选取2013年1月~2014年1月我院收治的96例UC患者作为研究对象，采用随机数字表法分为对照1组(n=32)、对照2组(n=32)和观察组(n=32)，对照1组采用美沙拉嗪治疗，对照2组采用双歧三联活菌治疗，观察组采用美沙拉嗪联合双歧三联活菌治疗，对三组患者的临床治疗效果进行观察和分析。结果观察组的治疗总有效率为90.63%，不良反应发生率为6.25%；对照1组的治疗总有效率为71.88%，不良反应发生率为31.25%；对照2组的治疗总有效率为75.00%，不良反应发生率为25.00%，三组差异有统计学意义(P<0.05)。结论对UC患者采用美沙拉嗪与双歧三联活菌联合治疗，能明显改善患者的临床症状，减少不良反应，疗效显著，从而提高患者的生活质量，值得临床推广应用。
目的：分析美沙拉嗪聯閤雙歧三聯活菌治療潰瘍性結腸炎(UC)的臨床效果。方法選取2013年1月~2014年1月我院收治的96例UC患者作為研究對象，採用隨機數字錶法分為對照1組(n=32)、對照2組(n=32)和觀察組(n=32)，對照1組採用美沙拉嗪治療，對照2組採用雙歧三聯活菌治療，觀察組採用美沙拉嗪聯閤雙歧三聯活菌治療，對三組患者的臨床治療效果進行觀察和分析。結果觀察組的治療總有效率為90.63%，不良反應髮生率為6.25%；對照1組的治療總有效率為71.88%，不良反應髮生率為31.25%；對照2組的治療總有效率為75.00%，不良反應髮生率為25.00%，三組差異有統計學意義(P<0.05)。結論對UC患者採用美沙拉嗪與雙歧三聯活菌聯閤治療，能明顯改善患者的臨床癥狀，減少不良反應，療效顯著，從而提高患者的生活質量，值得臨床推廣應用。
목적：분석미사랍진연합쌍기삼련활균치료궤양성결장염(UC)적림상효과。방법선취2013년1월~2014년1월아원수치적96례UC환자작위연구대상，채용수궤수자표법분위대조1조(n=32)、대조2조(n=32)화관찰조(n=32)，대조1조채용미사랍진치료，대조2조채용쌍기삼련활균치료，관찰조채용미사랍진연합쌍기삼련활균치료，대삼조환자적림상치료효과진행관찰화분석。결과관찰조적치료총유효솔위90.63%，불량반응발생솔위6.25%；대조1조적치료총유효솔위71.88%，불량반응발생솔위31.25%；대조2조적치료총유효솔위75.00%，불량반응발생솔위25.00%，삼조차이유통계학의의(P<0.05)。결론대UC환자채용미사랍진여쌍기삼련활균연합치료，능명현개선환자적림상증상，감소불량반응，료효현저，종이제고환자적생활질량，치득림상추엄응용。
Objective To analyze the clinical effects of mesalazine combined with dichotomous sanlian living bacterium in the treatment of ulcerative colitis(UC). Methods 96 patients with UC admitted into our hospital from January 2013 to January 2014 were selected as research objects.They were divided into control group 1,control group 2 and observation group by random number table,with 32 cases in each group.In the control group 1 was treated with mesalazine,control group 2 was treated with dichotomous sanlian living bacterium,observation group was treated with mesalazine combined with dichotomous sanlian living bacterium.The treatment effects in 3 groups were compared and analyzed. Results The effective rate in observation group was 90.63%,the adverse reactions occurred rate was 6.25%.The effective rate in con-trol group 1 was 71.88%,the adverse reactions occurred rate was 31.25%.The effective rate in control group 2 was 75.00%,the adverse reactions occurred rate was 25.00%.There was statistical significance among the 3 groups (P<0.05). Conclusion For patients with UC cured by mesalazine combined with dichotomous sanlian living bacterium,which can significantly improve the clinical symptoms,reduce adverse reactions,and has good clinical effect,so can improve the quality life of patients,it is worthy of clinic application.
